A review on the role of gut microbiota in immune checkpoint blockade therapy for cancer

Gut microbiota has been studied in relation to human health and disease prediction for decades. Also, immune checkpoints (ICPs) are enthusiastically investigated for anti-tumor immunotherapy. Recent studies show potential of gut microbiome and gut cytokines as biomarkers for carcinogenesis and response prediction of immune checkpoint inhibitor (ICI) response. Evidence has revealed that intestinal microorganisms play a major role in the effectiveness of programmed cell death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade. In this review, we have focused on how microbiome and microbiome-generated cytokines affect immune checkpoints. We have also described the molecular mechanisms behind this interplay and the bacterial strains that have a potential role in immunotherapy.

Automated summary

The gut microbiome and gut cytokines have shown potential as biomarkers for carcinogenesis and predicting response to immune checkpoint inhibitors, playing a significant role in the effectiveness of PD-1 and CTLA-4 blockade. Understanding the interplay between microbiome, microbiome-generated cytokines, and immune checkpoints may lead to new insights in immunotherapy.